376608-65-0

Basic information

• Product Name: 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid
• Synonyms: 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid;2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate;Ticagrelor InterMediate 2;2-[[(3aR, 4S, 6R, 6aS)6-aMinotetrahydro-2,2-diMethyl-4-H-cyclopenta-1,3-dioxol-4-yl]oxy]-(2R,3R)-2,3-dihydroxybutanedioate ethanol;2-((3aR,4R,6R,6aR)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid;2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tat;2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethan-1-ol (2R,3R)-2,3-dihydroxysuccinate;Ethanol, 2-[[(3aR,4S,6R,6aS)-6-aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)
• CAS NO: 376608-65-0
• Molecular Formula: C₄H₆O₆*C₁₀H₁₉NO₄
• Molecular Weight: 427
• EINECS: 1308068-626-2
• Product Categories: Intermediate of Ticagrelor
• Mol File: 376608-65-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid(376608-65-0)
• EPA Substance Registry System: 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid(376608-65-0)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 376608-65-0(Hazardous Substances Data)

Usage

Description

2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid is a complex organic compound with a unique molecular structure. It features a cyclopenta[d][1,3]dioxol ring system with multiple chiral centers and functional groups, including an amino group and an L-tataric acid moiety. 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid is characterized by its stereochemistry and the presence of multiple stereocenters, which contribute to its distinct properties and potential applications.

Uses

Used in Pharmaceutical Industry:
2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid is used as a building block for the synthesis of pharmaceutical compounds, particularly in the preparation of the antithrombotic agent Ticagrelor. Its unique structure and functional groups make it a valuable component in the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tataric acid can also be utilized in various chemical synthesis processes, where its specific stereochemistry and functional groups can be exploited to create new molecules with potential applications in different fields, such as materials science, agrochemicals, or specialty chemicals.

Upstream product

• 345898-95-5 N-(((4S,5R)-2,2-dimethyl-5-vinyl-1 ,3-dioxolan-4-yl)methylene)-1-phenylmethanamine oxide 
• 155899-66-4 (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 36468-53-8 β-D-ribofuranose 
• 274693-53-7 [3aS-(3aα,4α,6α,6aα)]-(tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl)carbamic acid phenylmethyl ester 
• 866551-95-3 ethyl 2-(6-(benzyloxycarbonylamino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy) acetate 
• 274693-54-8 benzyl 6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ylcarbamate 
• 274693-55-9 [3aR-(3aα,4α,6α,6aα)]-2-[[6-amino-2,2-dimethyl tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol 
• 87-69-4 L-Tartaric acid 
• 4099-85-8 ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 4137-56-8 methyl 2,3-O-isopropylidene-5-O-p-tolylsulfonyl-β-D-ribofuranoside 
• 38838-06-1 methyl 5-deoxy-5-iodo-2,3-isopropylidene-β-D-ribofuranoside 

Downstream Products

• 376608-74-1 2-[((3aR,4S,6R,6aS)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy]-1-ethanol 
• 274693-27-5 ticagrelor 
• 1402150-32-6 (1S 2S,3R,5S)-3-[(5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
• 1354945-69-9 9-[(1’R,2’S,3’S,4’S)-2’,3’-dihydroxyl-4'-hydroxyethoxycyclopenta-1'-yl]-9H-2-thiopropyl-6-chloro-8-azepine 
• 376608-75-2 2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol 
• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 1383715-59-0 2-[[(3aR,4S,6R,6aS)-6-[[4-[N-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-yl]-N-tert-butoxycarbonyl]amino]-2-(propylthio)-5-nitropyrimidin-6-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy] ethanol 

Relevant articles and documents

Synthesis method of ticagrelor key intermediate

The invention discloses a synthesis method of a ticagrelor key intermediate, which belongs to the technical field of medical technologies, and is technically characterized by comprising the following steps: S1, dissolving a compound I in an organic solvent, adding strong base, reacting with sodium bromoacetate or bromoacetic acid, and adding ethyl chloroformate to synthesize a compound II; S2, adding sodium borohydride into the solution of the compound II in batches to obtain a compound III; and S3, deprotecting the compound III under the action of ammonium formate and 10% palladium on carbon, and then adding Ltartaric acid for salifying to synthesize a compound IV. The invention aims to provide a synthesis method of a ticagrelor key intermediate. The cost is effectively reduced, the synthesis process is simplified, and the method is suitable for large-scale production.